Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Lymphoid 1

Conditions

Spinal Cord Neoplasms 1Pinealoma 1Glioma 1Glioblastoma 1Choroid Plexus Carcinoma 1Central Nervous System Neoplasms 1

Interventions

Temozolomide 166Magnetic Resonance Spectroscopy 131Radiotherapy 97Specimen Handling 81Radiosurgery 61Cyclophosphamide 56pembrolizumab 52Bevacizumab 52Radiation 48Nivolumab 48Carboplatin 36Biopsy 33Irinotecan 29Etoposide 25Vincristine 24Lomustine 24Topotecan 23Ipilimumab 23Blood Specimen Collection 23Cisplatin 22dinutuximab 21fludarabine 19Surgical Procedures, Operative 19Radiotherapy, Intensity-Modulated 19X-Rays 18abemaciclib 16Mental Status and Dementia Tests 16Granulocyte-Macrophage Colony-Stimulating Factor 16Pemetrexed 15atezolizumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
perillyl alcohol × CNS × 1 year × Clear all
NCT02704858 2026-03-02

Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma

Neonc Technologies, Inc.

Phase 1/2 Recruiting
49 enrolled
CNS

Glioblastoma

NCT06357377 2026-01-14

A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors

Neonc Technologies, Inc.

Phase 1 Not yet recruiting
12 enrolled
CNS

Choroid Plexus Carcinoma, Glioma, Pinealoma, Spinal Cord Neoplasms, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡